

rhabdomyosarcoma, and prostate, ovarian, colorectal, and lung cancers.

Competitive Advantages:

- High affinity of the CARs increases the likelihood of successful targeting.

- Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients.

Development Stage:

- Early-stage.
- In vitro data available.

Inventors: Rimantas J. Orentas, et al. (NCI).

Intellectual Property: HHS Reference No. E-104-2013/0-US-01-US Provisional Patent Application No. 61/805,001 filed 25 March 2013.

Related Technologies:

- HHS Reference No. E-291-2012/0—International Patent Application No. PCT/US2013/060332 filed 18 September 2013; “M971 Chimeric Antigen Receptors,” Orentas R, et al.
- HHS Reference No. E-007-2014/0—US Provisional Patent Application No. 61/865,845 filed 06 November 2013; “ALK Specific Chimeric Antigen Receptors,” Orentas R, Mackall C.

Licensing Contact: David A.

Lambertson, Ph.D.; 301-435-4632; lambertson@mail.nih.gov.

Collaborative Research Opportunity: The Pediatric Oncology Branch, CCR, NCI, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize chimeric antigen receptors (CARs) specific for tumor-expressed CD276 (B7-H3). For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewes@mail.nih.gov.

Bispecific Antibodies To Target Latent HIV-1 Infection

Description of Technology: The invention describes bispecific antibodies designed to kill latently HIV-1 infected T cells. It is thought that such bispecific antibodies will reduce or eliminate the pool of HIV-1 infected cells, contributing to functional cure. The antibody constructs comprise an HIV Env-binding fragment of a broadly neutralizing antibody linked to an anti-CD3 single chain variable fragment (scFv). One embodiment is a VRC01 scFv linked to the anti-CD3 scFv. Other embodiments comprise Fab fragments of VRC07 or 10E8 antibodies linked to the anti-CD3 scFv. The bispecific antibody simultaneously stimulates infected cells to express gp120, instructs cytotoxic T cells to kill these cells, and neutralizes extraneous viral particles.

Potential Commercial Applications: Immunotherapy of HAART-suppressed HIV-1 infection.

Competitive Advantages:

- Immunotherapy targets latently infected cells harboring virus resistant to HAART.

- Broadly neutralizing antibody fragment neutralizes extraneous viral particles.

Development Stage:

- Pre-clinical.
- In vivo data available (animal).

Inventors: Gary J. Nabel, Xiaoti Guo, Amarendra Pegu, Zhi-yong Yang (all of NIAID).

Intellectual Property:

- HHS Reference No. E-071-2012/0—US Application No. 61/638,437 filed 25 April 2012.

- HHS Reference No. E-071-2012/1—PCT Application No. PCT/US2013/038214 filed 25 April 2013, which published as WO 2013/163427 on 31 October 2013.

Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-435-4507; ThalhamC@mail.nih.gov.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases, Vaccine Research Center, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize HIV-1 bispecific antibodies. For collaboration opportunities, please contact Barry Buchbinder, Ph.D. at 301-594-1696.

Dated: January 2, 2014.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2014-00123 Filed 1-8-14; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases: Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

Date: February 11, 2014.

Open: 8:30 a.m. to 12:30 p.m.

Agenda: Discussion of Program Policies.

Place: National Institutes of Health, Building 31, Room 6, 31 Center Drive, Bethesda, MD 20892.

Closed: 1:30 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, Room 6, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Laura K. Moen, Ph.D., Director, Division of Extramural Research Activities, NIAMS/NIH, 6700 Democracy Boulevard, Suite 800, Bethesda, MD 20892, 301-451-6515 moenl@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS).

Dated: January 2, 2014.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014-00125 Filed 1-8-14; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as